fbpx

Noradrenaline

CLASS

  • endogenous catecholamine

MECHANISM OF ACTION

  • direct alpha and beta adrenergic receptor agonist (vasopressor and weak inotropes)
  • alpha > beta
  • alpha effects:
    — increased SVR -> increased afterload; increased DBP and coronary perfusion pressure
    — increased venoconstriction -> increased venous return -> increased preload
  • beta effects:
    — inotropy and chronotropy

PHARMACEUTICS

  • clear, colorless solution, 2mg/mL, norepinephrine bitartrate

DOSE

  • 0.1 to 1 mcg/kg/min IV via central line

INDICATIONS

  • hypotension refractory to fluid resuscitation (primarily distributive shock such as septic shock, neurogenic shock, post-bypass vasoplegia and drug-induced)

ADVERSE EFFECTS

  • hypertension
  • reflex bradycardia
  • hyperglycaemia
  • increased afterload and beta effects may increased myocardial work and oxygen consumption
  • peripheral ischaemia

PHARMACOKINETICS

  • Absorption – IV (preferably via CVL)
  • Distribution – small Vd
  • Metabolism – MAO and COMT
  • Elimination – short t1/2, unchanged in urine

Evidence

Cochrane Review 2011

  • 23 RCT’s
  • n = 3212
  • 6 different vasopressors (alone or in combination with dobutamine or dopexamine)
  • -> dopamine: increased risk of arrhythmias
  • -> no significant evidence to say that one is better than the other

VAAST Trial 2008 NEJM

  • DB MC RCT
  • n = 780
  • Vasopressin vs noradrenaline
  • Patients on low dose Norad randomised to Vasopressin vs Norad
  • -> no significant difference in mortality @ 28 days

CAT Study, 2009 Int Care Med

  • Australasian MC DB RCT
  • Noradrenaline vs Adrenaline to treat hypotension (sepsis or cardiogenic failure)
  • n = 208
  • -> no significant difference in mortality, LOS, ventilation, shock duration
  • -> adrenaline – transient lactic acidosis, hyperglycaemia, tachycardia

Annane et al, 2007 Lancet

  • MC RCT
  • n = 330
  • noradrenaline vs adrenaline in Septic Shock
  • -> no significant difference: mortality, BP, time to haemodynamic stability, duration of vasopressor therapy, time to organ dysfunction resolution, adverse effects
  • -> criticisms = underpowered, methodology suboptimal, strict inclusion criteria

Martin et al, 2000 CCM

  • effect of norepinephrine on the outcome of septic shock
  • n = 97 adults septic shock
  • low dose dopamine then randomized to high dose dopamine vs noradrenaline
  • adrenaline added if non-responding
  • -> use of noradrenaline strongly related (p<0.001) to favorable outcome considered protective, markedly decreased hospital mortality
  • -> Splanchnic function not worsened by NA

CCC Pharmacology Series

Journal articles

  • Myburgh J. Norepinephrine: more of a neurohormone than a vasopressor. Crit Care. 2010;14(5):196. doi: 10.1186/cc9246. Epub 2010 Sep 20. PMC3219251.
  • Myburgh JA. An appraisal of selection and use of catecholamines in septic shock – old becomes new again. Crit Care Resusc. 2006 Dec;8(4):353-60. Review. PubMed PMID: 17227275.

FOAM and web resources

Critical Care

Compendium

Chris is an Intensivist and ECMO specialist at The Alfred ICU, where he is Deputy Director (Education). He is a Clinical Adjunct Associate Professor at Monash University, the Lead for the  Clinician Educator Incubator programme, and a CICM First Part Examiner.

He is an internationally recognised Clinician Educator with a passion for helping clinicians learn and for improving the clinical performance of individuals and collectives. He was one of the founders of the FOAM movement (Free Open-Access Medical education) has been recognised for his contributions to education with awards from ANZICS, ANZAHPE, and ACEM.

His one great achievement is being the father of three amazing children.

On Bluesky, he is @precordialthump.bsky.social and on the site that Elon has screwed up, he is @precordialthump.

| INTENSIVE | RAGE | Resuscitology | SMACC

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.